Novartis Ends Discovery Work With BioArctic on Brain-Delivery Technology
- Novartis has ended its discovery-stage collaboration with Sweden's BioArctic, the company behind Alzheimer's drug Leqembi.
- The 2025 agreement covered BioArctic's BrainTransporter blood-brain-barrier technology, with a $30 million initial payment and up to $772 million in milestones.
💡 Points Based on public reports
Discovery-stage terminations are cheap and common, and almost none of the $772 million headline was ever at risk, so the signal is mostly about BioArctic's brain-delivery platform not clearing Novartis's internal bar. It also loses a partner after AbbVie exited a separate alpha-synuclein pact, leaving Lilly as the other named BrainTransporter partner. A clinical proof-of-concept, not another discovery deal, is what would restore confidence in the platform.
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance ↗